CONCENTRATIONS AND CREDIT RISK |
3 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Risks and Uncertainties [Abstract] | |
| CONCENTRATIONS AND CREDIT RISK | NOTE 13. CONCENTRATIONS AND CREDIT RISK
Revenues
Two customers accounted for approximately 73 % of the Company’s revenues for the three months ended June 30, 2026. These customers accounted for approximately 60% and 13% of revenues, respectively.
Three customers accounted for approximately 76% of the Company’s revenues for the three months ended June 30, 2025. These three customers accounted for approximately 51%, 15% and 10% of revenues, respectively.
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Accounts Receivable
Two customers accounted for approximately 76 % of the Company’s accounts receivable as of June 30, 2026. These two customers accounted for approximately 66% and 10% of receivables, respectively.
Three customers accounted for approximately 77% of the Company’s accounts receivable as of June 30, 2025. These three customers accounted for approximately 54%, 12% and 11% of accounts receivable, respectively.
Purchasing
Three suppliers accounted for approximately 78% of the Company’s purchases of raw materials for the three months ended June 30, 2026. These three suppliers accounted for approximately 32%, 31%, and 14% of purchasing, respectively.
Three suppliers accounted for approximately 75% of the Company’s purchases of raw materials for the three months ended June 30, 2025. These three suppliers accounted for approximately 31%, 25%, and 19% of purchasing, respectively.
|